GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (TSXV:KNE) » Definitions » EBIT

Kane Biotech (TSXV:KNE) EBIT : C$-4.15 Mil (TTM As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Kane Biotech EBIT?

Kane Biotech's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was C$-0.61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-4.15 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kane Biotech's annualized ROC % for the quarter that ended in Sep. 2024 was -99.71%. Kane Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -249.72%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kane Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -25.94%.


Kane Biotech EBIT Historical Data

The historical data trend for Kane Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kane Biotech EBIT Chart

Kane Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.82 -3.72 -4.43 -3.21 -3.35

Kane Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.97 -1.25 -1.18 -1.12 -0.61

Competitive Comparison of Kane Biotech's EBIT

For the Biotechnology subindustry, Kane Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kane Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kane Biotech's EV-to-EBIT falls into.



Kane Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kane Biotech  (TSXV:KNE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kane Biotech's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-2.444 * ( 1 - 0% )/( (2.761 + 2.141)/ 2 )
=-2.444/2.451
=-99.71 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Kane Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.456/( ( (1.001 + max(-1.219, 0)) + (0.966 + max(-1.087, 0)) )/ 2 )
=-2.456/( ( 1.001 + 0.966 )/ 2 )
=-2.456/0.9835
=-249.72 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.295 + 0.728 + 0.167) - (1.814 + 0.595 + -4.4408920985006E-16)
=-1.219

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.344 + 0.688 + 0.193) - (2.312 + 0 + 0)
=-1.087

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kane Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-4.153/16.013
=-25.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kane Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Kane Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Kane Biotech Business Description

Traded in Other Exchanges
Address
290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.
Executives
Marc Edwards Director
Philip Renaud Director
Raymond David Eugene Dupuis Senior Officer
Richard J. Renaud 10% Security Holder
Georges Morin Director
Rashieda Gluck Director

Kane Biotech Headlines

No Headlines